Metabolic (dysfunction)-associated fatty liver disease (MAFLD) affects up to a third of the
global population; its burden has grown in parallel with rising rates of type 2 diabetes …

Nonalcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD) are the
leading causes of chronic liver disease worldwide. NAFLD and ALD share …

Non-alcoholic fatty liver disease (NAFLD) is regarded as a pandemic that affects about a
quarter of the global population. Recently, host-gut microbiota metabolic interactions have …

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for
steatotic liver disease associated with metabolic syndrome. MASLD is the most common …

Abstract Background and Objective The aim of the present study is to explore the
epidemiologic impact of the definition of steatotic liver disease (SLD) proposed by a multi …

Steatotic liver disease (SLD) displays a dynamic and complex disease phenotype.
Consequently, the metabolic dysfunction-associated steatotic liver disease …

With the rising tide of fatty liver disease related to metabolic dysfunction worldwide, the
association of this common liver disease with chronic kidney disease (CKD) has become …

Globally, nearly half of deaths from cirrhosis and chronic liver diseases (CLD) and three-
quarters of deaths from hepatocellular carcinoma (HCC) occur in the Asia-Pacific region …

Nonalcoholic fatty liver disease (NAFLD) is a global pandemic that affects one-quarter of the
world's population. NAFLD includes a spectrum of progressive liver disease from steatosis to …

Modifications in the microbiota caused by environmental and genetic reasons can
unbalance the intestinal homeostasis, deregulating the host's metabolism and immune …